A citation-based method for searching scientific literature

Aubhishek Zaman, Trever G Bivona. Ann Transl Med 2018
Times Cited: 13







List of co-cited articles
25 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity




Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, Paul Baas, Lucio Crinò, Wilfried E E Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Pluzanski, Everett E Vokes, Esther Holgado,[...]. N Engl J Med 2015
15

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
15

Comprehensive genomic profiles of small cell lung cancer.
Julie George, Jing Shan Lim, Se Jin Jang, Yupeng Cun, Luka Ozretić, Gu Kong, Frauke Leenders, Xin Lu, Lynnette Fernández-Cuesta, Graziella Bosco,[...]. Nature 2015
905
15

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
15

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, Leora Horn, David R Spigel, Martin Steins, Neal E Ready, Laura Q Chow, Everett E Vokes, Enriqueta Felip, Esther Holgado,[...]. N Engl J Med 2015
15

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M Gadgeel, Toyoaki Hida, Dariusz M Kowalski, Manuel Cobo Dols,[...]. Lancet 2017
15

Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy.
Gloria Manzotti, Alessia Ciarrocchi, Valentina Sancisi. Cancers (Basel) 2019
32
15

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.
Ethan Cerami, Jianjiong Gao, Ugur Dogrusoz, Benjamin E Gross, Selcuk Onur Sumer, Bülent Arman Aksoy, Anders Jacobsen, Caitlin J Byrne, Michael L Heuer, Erik Larsson,[...]. Cancer Discov 2012
15

Role of YAP/TAZ in mechanotransduction.
Sirio Dupont, Leonardo Morsut, Mariaceleste Aragona, Elena Enzo, Stefano Giulitti, Michelangelo Cordenonsi, Francesca Zanconato, Jimmy Le Digabel, Mattia Forcato, Silvio Bicciato,[...]. Nature 2011
15

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.
Luping Lin, Amit J Sabnis, Elton Chan, Victor Olivas, Lindsay Cade, Evangelos Pazarentzos, Saurabh Asthana, Dana Neel, Jenny Jiacheng Yan, Xinyuan Lu,[...]. Nat Genet 2015
295
15

TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells.
M Bartucci, R Dattilo, C Moriconi, A Pagliuca, M Mottolese, G Federici, A Di Benedetto, M Todaro, G Stassi, F Sperati,[...]. Oncogene 2015
210
15

BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones.
Tomohiko Kanno, Yuka Kanno, Gary LeRoy, Eric Campos, Hong-Wei Sun, Stephen R Brooks, Golnaz Vahedi, Tom D Heightman, Benjamin A Garcia, Danny Reinberg,[...]. Nat Struct Mol Biol 2014
162
15

Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis.
Allison N Lau, Stephen J Curtis, Christine M Fillmore, Samuel P Rowbotham, Morvarid Mohseni, Darcy E Wagner, Alexander M Beede, Daniel T Montoro, Kerstin W Sinkevicius, Zandra E Walton,[...]. EMBO J 2014
139
15

Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
Marco Gerlinger, Andrew J Rowan, Stuart Horswell, M Math, James Larkin, David Endesfelder, Eva Gronroos, Pierre Martinez, Nicholas Matthews, Aengus Stewart,[...]. N Engl J Med 2012
15

Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma.
Banu Eskiocak, Elizabeth A McMillan, Saurabh Mendiratta, Rahul K Kollipara, Hailei Zhang, Caroline G Humphries, Changguang Wang, Jose Garcia-Rodriguez, Ming Ding, Aubhishek Zaman,[...]. Cancer Discov 2017
28
15

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
Robert J Nichols, Franziska Haderk, Carlos Stahlhut, Christopher J Schulze, Golzar Hemmati, David Wildes, Christos Tzitzilonis, Kasia Mordec, Abby Marquez, Jason Romero,[...]. Nat Cell Biol 2018
128
15

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.
Collin M Blakely, Thomas B K Watkins, Wei Wu, Beatrice Gini, Jacob J Chabon, Caroline E McCoach, Nicholas McGranahan, Gareth A Wilson, Nicolai J Birkbak, Victor R Olivas,[...]. Nat Genet 2017
254
15

Global cancer statistics, 2012.
Lindsey A Torre, Freddie Bray, Rebecca L Siegel, Jacques Ferlay, Joannie Lortet-Tieulent, Ahmedin Jemal. CA Cancer J Clin 2015
15


Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Zhenfeng Zhang, Jae Cheol Lee, Luping Lin, Victor Olivas, Valerie Au, Thomas LaFramboise, Mohamed Abdel-Rahman, Xiaoqi Wang, Alan D Levine, Jin Kyung Rho,[...]. Nat Genet 2012
795
15

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata,[...]. N Engl J Med 2018
15

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.
Sreenath V Sharma, Diana Y Lee, Bihua Li, Margaret P Quinlan, Fumiyuki Takahashi, Shyamala Maheswaran, Ultan McDermott, Nancy Azizian, Lee Zou, Michael A Fischbach,[...]. Cell 2010
15

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
Klarisa Rikova, Ailan Guo, Qingfu Zeng, Anthony Possemato, Jian Yu, Herbert Haack, Julie Nardone, Kimberly Lee, Cynthia Reeves, Yu Li,[...]. Cell 2007
15


Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms.
Phuc H Hoang, Sara E Dobbins, Alex J Cornish, Daniel Chubb, Philip J Law, Martin Kaiser, Richard S Houlston. Leukemia 2018
41
7

Risk Stratification in Multiple Myeloma.
Melissa Gaik-Ming Ooi, Sanjay de Mel, Wee Joo Chng. Curr Hematol Malig Rep 2016
9
11

Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma.
Efstathios Kastritis, Evangelos Terpos, Maria Roussou, Maria Gavriatopoulou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Despoina Fotiou, Dimitrios Ziogas, Ioannis Panagiotidis, Eftychia Kafantari,[...]. Haematologica 2017
43
7

A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5.
Brian S White, Irena Lanc, Julie O'Neal, Harshath Gupta, Robert S Fulton, Heather Schmidt, Catrina Fronick, Edward A Belter, Mark Fiala, Justin King,[...]. Blood Cancer J 2018
22
7

Is the revised International staging system for myeloma valid in a real world population?
Ieuan Walker, Alice Coady, Michael Neat, Darius Ladon, Reuben Benjamin, Inas El-Najjar, Majid Kazmi, Steve Schey, Matthew Streetly. Br J Haematol 2018
7
14

International staging system for multiple myeloma.
Philip R Greipp, Jesus San Miguel, Brian G M Durie, John J Crowley, Bart Barlogie, Joan Bladé, Mario Boccadoro, J Anthony Child, Herve Avet-Loiseau, Robert A Kyle,[...]. J Clin Oncol 2005
7

Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients.
Verónica González-Calle, Abigail Slack, Niamh Keane, Susan Luft, Kathryn E Pearce, Rhett P Ketterling, Tania Jain, Sintosebastian Chirackal, Craig Reeder, Joseph Mikhael,[...]. Ann Hematol 2018
16
7

Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma.
N Tandon, S V Rajkumar, B LaPlant, A Pettinger, M Q Lacy, A Dispenzieri, F K Buadi, M A Gertz, S R Hayman, N Leung,[...]. Blood Cancer J 2017
20
7

The Revised International Staging System Compared to the Classical International Staging System Better Discriminates Risk Groups among Transplant-Ineligible Multiple Myeloma Patients.
Jelena Bila, Jelena Jelicic, Marija Dencic Fekete, Goran Trajkovic, Aleksandra Sretenovic, Maja Perunicic Jovanovic, Darko Antic, Biljana Mihaljevic. Oncol Res Treat 2017
5
20

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.
Donavan T Cheng, Talia N Mitchell, Ahmet Zehir, Ronak H Shah, Ryma Benayed, Aijazuddin Syed, Raghu Chandramohan, Zhen Yu Liu, Helen H Won, Sasinya N Scott,[...]. J Mol Diagn 2015
948
7

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.
Brian A Walker, Eileen M Boyle, Christopher P Wardell, Alex Murison, Dil B Begum, Nasrin M Dahir, Paula Z Proszek, David C Johnson, Martin F Kaiser, Lorenzo Melchor,[...]. J Clin Oncol 2015
309
7

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
Pieter Sonneveld, Hervé Avet-Loiseau, Sagar Lonial, Saad Usmani, David Siegel, Kenneth C Anderson, Wee-Joo Chng, Philippe Moreau, Michel Attal, Robert A Kyle,[...]. Blood 2016
415
7

Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy.
Hyungwoo Cho, Dok Hyun Yoon, Jung Bok Lee, Sung-Yong Kim, Joon Ho Moon, Young Rok Do, Jae Hoon Lee, Yong Park, Ho Sup Lee, Hyeon Seok Eom,[...]. Am J Hematol 2017
17
7

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.
Antonio Palumbo, Hervé Avet-Loiseau, Stefania Oliva, Henk M Lokhorst, Hartmut Goldschmidt, Laura Rosinol, Paul Richardson, Simona Caltagirone, Juan José Lahuerta, Thierry Facon,[...]. J Clin Oncol 2015
833
7

High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma.
A Miller, Y Asmann, L Cattaneo, E Braggio, J Keats, D Auclair, S Lonial, S J Russell, A K Stewart. Blood Cancer J 2017
78
7

Histone H3K27ac separates active from poised enhancers and predicts developmental state.
Menno P Creyghton, Albert W Cheng, G Grant Welstead, Tristan Kooistra, Bryce W Carey, Eveline J Steine, Jacob Hanna, Michael A Lodato, Garrett M Frampton, Phillip A Sharp,[...]. Proc Natl Acad Sci U S A 2010
7

Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model.
Ralph Meuwissen, Sabine C Linn, R Ilona Linnoila, John Zevenhoven, Wolter J Mooi, Anton Berns. Cancer Cell 2003
359
7

Angiogenesis Inhibitors in NSCLC.
Anna Manzo, Agnese Montanino, Guido Carillio, Raffaele Costanzo, Claudia Sandomenico, Nicola Normanno, Maria Carmela Piccirillo, Gennaro Daniele, Francesco Perrone, Gaetano Rocco,[...]. Int J Mol Sci 2017
34
7

Expression of aminopeptidase N/CD13 in human ovarian cancers.
P Surowiak, M Drag, V Materna, S Suchocki, R Grzywa, M Spaczyński, M Dietel, J Oleksyszyn, M Zabel, H Lage. Int J Gynecol Cancer 2006
37
7



Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer.
Reika Iwakawa, Masataka Takenaka, Takashi Kohno, Yoko Shimada, Yasushi Totoki, Tatsuhiro Shibata, Koji Tsuta, Ryo Nishikawa, Masayuki Noguchi, Aiko Sato-Otsubo,[...]. Genes Chromosomes Cancer 2013
82
7

Monoclonal antibodies in cancer therapy.
R K Oldham. J Clin Oncol 1983
93
7

A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer.
M Catherine Pietanza, Anya M Litvak, Anna M Varghese, Lee M Krug, Martin Fleisher, Jerrold B Teitcher, Andrei I Holodny, Cami S Sima, Kaitlin M Woo, Kenneth K Ng,[...]. Lung Cancer 2016
41
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.